# A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

> **NCT03669640** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 131 (actual)

## Conditions studied

- Schizophrenia, Schizoaffective Disorder

## Interventions

- **DRUG:** RO6889450
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03669640
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-04
- **Primary completion:** 2023-03-12
- **Final completion:** 2023-03-12
- **Target enrollment:** 131 (ACTUAL)
- **Why stopped:** This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669640, "A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03669640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*